Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.71)
# 4,016
Out of 5,048 analysts
58
Total ratings
32%
Success rate
-25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $5.92 | +85.81% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $20.62 | +50.34% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $0.96 | +1,880.40% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $7.68 | +173.44% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $3.74 | +33.69% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $2.33 | +586.70% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $1.50 | +7,900.00% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $6.07 | +311.86% | 2 | May 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $104.75 | - | 3 | Mar 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $2,000 | $6.18 | +32,262.46% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.40 | +400.00% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.68 | +171.74% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $15.43 | +288.85% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.64 | +265.85% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.03 | +148.14% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $2.00 | +11,900.00% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $10.02 | +1,716.37% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.37 | +21,580.22% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.29 | +366.20% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.98 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.38 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.54 | +136.22% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $6.36 | +230.19% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $10.33 | +101,545.69% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.02 | +1,731.68% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $59.92 | +400.67% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $642.25 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $101.57 | -12.38% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $141.96 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $15,000 | $3.62 | +414,264.64% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $2.50 | +13,340.00% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.58 | +293.01% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $5.92
Upside: +85.81%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $20.62
Upside: +50.34%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $0.96
Upside: +1,880.40%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $7.68
Upside: +173.44%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $3.74
Upside: +33.69%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $2.33
Upside: +586.70%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $1.50
Upside: +7,900.00%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $6.07
Upside: +311.86%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $104.75
Upside: -
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $6.18
Upside: +32,262.46%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.40
Upside: +400.00%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $3.68
Upside: +171.74%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $15.43
Upside: +288.85%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.64
Upside: +265.85%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.03
Upside: +148.14%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $2.00
Upside: +11,900.00%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $10.02
Upside: +1,716.37%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.37
Upside: +21,580.22%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $4.29
Upside: +366.20%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $11.98
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.38
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $2.54
Upside: +136.22%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $6.36
Upside: +230.19%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $10.33
Upside: +101,545.69%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.02
Upside: +1,731.68%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $59.92
Upside: +400.67%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $642.25
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $101.57
Upside: -12.38%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $141.96
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $15,000
Current: $3.62
Upside: +414,264.64%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $2.50
Upside: +13,340.00%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $4.58
Upside: +293.01%